Albert P. Parker - 24 Jan 2023 Form 4 Insider Report for Zynerba Pharmaceuticals, Inc.

Role
Chief Legal Officer
Signature
/s/ Albert P. Parker
Issuer symbol
N/A
Transactions as of
24 Jan 2023
Net transactions value
$0
Form type
4
Filing time
25 Jan 2023, 16:30:17 UTC
Previous filing
15 Feb 2022
Next filing
02 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZYNE Common Stock Award $0 +170,000 +486% $0.000000 205,000 24 Jan 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted stock award will fully vest in two installments, subject to continued employment with the Company through the applicable vesting date: 1/3 of the restricted stock will vest on February 1, 2024; and 2/3 of the restricted stock will vest on February 1, 2025.